美国生物制药公司Madrigal Pharmaceuticals, Inc.(简称Madrigal)在2024年10月31日盘前大涨17.4%,股价一度触及253.55美元,创下近两个月新高。这主要得益于该公司旗舰药品Rezdiffra在上一季度表现亮眼。
Rezdiffra是首个获得美国FDA批准的NASH(非酒精性脂肪性肝炎)治疗药物。数据显示,该药在2024年第三季度实现销售额6220万美元,大幅超过华尔街预期的3420万美元。这是Rezdiffra连续第二个季度取得强劲上市执行,进一步增强了市场对其潜在患者/用药者需求的信心。
分析人士表示,作为NASH领域的先行者,Madrigal公司有望利用其先发优势和商业经验来抓住这一新兴市场的机遇。NASH疾病约影响着5%的美国人口,患者基数庞大,潜在市场前景广阔。Rezdiffra出色的销售表现正持续提振着投资者的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.